{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:40:28Z","timestamp":1777516828187,"version":"3.51.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lung cancer metastases to bone produce a primarily mixed osteolytic\/osteoblastic lesion. The purpose of this study was to determine if blockade of both pathways would inhibit the formation these lesions in bone. Inhibition of the osteoblastic lesion with noggin and the osteolytic lesion with RANK:Fc was a successful treatment strategy to inhibit progression of mixed lung cancer lesions in bone.<\/jats:p>\n               <jats:p>Introduction: Approximately 9\u201330% of patients with lung cancer develop bone metastases, leading to significant morbidity and mortality. A549 is a non\u2013small-cell lung cancer (NSCLC) line that produces a mixed metastatic lesion in bone. We sought to determine if blockade of key components in both osteolytic and osteoblastic pathways would result in a reduction of a NSCLC tumor progression in a murine model of bony metastasis.<\/jats:p>\n               <jats:p>Materials and Methods: The study used a retroviral vector overexpressing noggin (RN), a specific inhibitor of BMP, and RANK:Fc, a chimeric protein that inhibits the RANK\u2013RANKL interaction. A549 cells were transduced with RN before implantation in SCID mice. Cells were implanted in a subcutaneous model and tibial injection model. RANK:Fc was administered twice weekly at 15 mg\/kg. There were five treatment groups: A549; A549 + RN; A549 + RANK:Fc; A549 + empty vector; and A549 + RN + RANK:Fc (n = 10\/group).<\/jats:p>\n               <jats:p>Results: In SCID mice who underwent subcutaneous A549 tumor cell injection, animals treated with A549 + RN had significantly smaller subcutaneous tumor size at 8 weeks. In an intratibial model of bony metastasis, animals injected with A549 cells developed a mixed lytic\/blastic lesion with cortical destruction at 8 weeks. Treatment with RANK:Fc inhibited the formation of osteoclasts, led to a smaller tumor volume in bone, and inhibited the lytic component of the mixed lesion. Animals treated with A549 + RN had a decreased number of osteoblasts in bone lesions, smaller tumor volume, and inhibition of the blastic component of the mixed lesions. Combination treatment inhibited both the lytic and blastic components of the lesion.<\/jats:p>\n               <jats:p>Conclusions: The NSCLC cell line A549 forms a mixed osteolytic\/osteoblastic lesion in vivo. Noggin overexpression inhibited the formation of the osteoblastic aspect of the lesion in bone and the tumor growth in vivo. Treatment with RANK:Fc limited the formation of the lytic aspect of the mixed lesion and also inhibited the rate of in vivo tumor growth. Inhibition of both pathways is necessary to effectively inhibit the progression of mixed metastatic lesions in bone.<\/jats:p>","DOI":"10.1359\/jbmr.060706","type":"journal-article","created":{"date-parts":[[2006,9,22]],"date-time":"2006-09-22T16:14:14Z","timestamp":1158941654000},"page":"1571-1580","source":"Crossref","is-referenced-by-count":103,"title":["Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration"],"prefix":"10.1093","volume":"21","author":[{"given":"Brian T","family":"Feeley","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy Q","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustine H","family":"Conduah","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Krenek","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C","family":"Dougall","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny","family":"Huard","sequence":"additional","affiliation":[{"name":"Departments of Orthopaedic Surgery and Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Dubinett","sequence":"additional","affiliation":[{"name":"Jonnson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay R","family":"Lieberman","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013021124803800_bib1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jnci\/djg040","article-title":"Annual report to the nation on the status of cancer, 1975\u20132000, featuring the uses of surveillance data for cancer prevention and control","volume":"95","author":"Weir","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2024013021124803800_bib2","first-page":"204","article-title":"Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs","volume":"7","author":"Yoshino","year":"2001","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"2024013021124803800_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jor.1100170217","article-title":"Bone morphogenetic proteins: An update on basic biology and clinical relevance","volume":"17","author":"Schmitt","year":"1999","journal-title":"J Orthop Res"},{"key":"2024013021124803800_bib4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1359\/JBMR.050802","article-title":"Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer","volume":"20","author":"Feeley","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024013021124803800_bib5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/0008-5472.CAN-03-1382","article-title":"Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein","volume":"64","author":"Dai","year":"2004","journal-title":"Cancer Res"},{"key":"2024013021124803800_bib6","first-page":"2189","article-title":"Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions","volume":"20","author":"Feeley","year":"2005","journal-title":"Bone"},{"key":"2024013021124803800_bib7","first-page":"89","article-title":"Differential expression and regulation of bone morphogenetic protein 7 in breast cancer","volume":"23","author":"Schwalbe","year":"2003","journal-title":"Int J Oncol"},{"key":"2024013021124803800_bib8","first-page":"143","article-title":"Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells","volume":"20","author":"Gobbi","year":"2002","journal-title":"Int J Oncol"},{"key":"2024013021124803800_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/jcp.55.5.381","article-title":"The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter","volume":"55","author":"Sulzbacher","year":"2002","journal-title":"J Clin Pathol"},{"key":"2024013021124803800_bib10","first-page":"5022","article-title":"Growth regulation of human prostate cancer cells by bone morphogenetic protein-2","volume":"57","author":"Ide","year":"1997","journal-title":"Cancer Res"},{"key":"2024013021124803800_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/pros.10193","article-title":"Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer","volume":"54","author":"Masuda","year":"2003","journal-title":"Prostate"},{"key":"2024013021124803800_bib12","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.athoracsur.2005.03.094","article-title":"Expression of bone morphogenetic proteins in human lung carcinomas","volume":"80","author":"Langenfeld","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"2024013021124803800_bib13","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/carcin\/bgg100","article-title":"The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells","volume":"24","author":"Langenfeld","year":"2003","journal-title":"Carcinogenesis"},{"key":"2024013021124803800_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1541-7786.141.2.3","article-title":"Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors","volume":"2","author":"Langenfeld","year":"2004","journal-title":"Mol Cancer Res"},{"key":"2024013021124803800_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.cr.7290266","article-title":"Mechanisms of cancer metastasis to the bone","volume":"15","author":"Yin","year":"2005","journal-title":"Cell Res"},{"key":"2024013021124803800_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4419-9129-4_7","article-title":"Opg, RANKl, and RANK in cancer metastasis: Expression and regulation","volume":"118","author":"Brown","year":"2004","journal-title":"Cancer Treat Res"},{"key":"2024013021124803800_bib17","first-page":"49","article-title":"RANKL\/RANK\/OPG: New therapeutic targets in bone tumours and associated osteolysis","volume":"1704","author":"Wittrant","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"2024013021124803800_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","article-title":"RANK ligand is a prerequisite for cancer-associated osteolytic lesions","volume":"198","author":"Kitazawa","year":"2002","journal-title":"J Pathol"},{"key":"2024013021124803800_bib19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.orthres.2005.05.004.1100230634","article-title":"The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone","volume":"23","author":"Whang","year":"2005","journal-title":"J Orthop Res"},{"key":"2024013021124803800_bib20","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1359\/jbmr.2003.18.9.1593","article-title":"ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development","volume":"18","author":"Zhang","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"3 Suppl","key":"2024013021124803800_bib21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.11134","article-title":"RANK-Fc: A therapeutic antagonist for RANK-L in myeloma","volume":"97","author":"Sordillo","year":"2003","journal-title":"Cancer"},{"key":"2024013021124803800_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0736-0266(02)00095-5","article-title":"Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone","volume":"21","author":"Lee","year":"2003","journal-title":"J Orthop Res"},{"key":"2024013021124803800_bib23","first-page":"5564","article-title":"Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model","volume":"62","author":"Lee","year":"2002","journal-title":"Cancer Res"},{"key":"2024013021124803800_bib24","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0090-4295(98)00658-X","article-title":"New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade","volume":"53","author":"Nelson","year":"1999","journal-title":"Urology"},{"issue":"3 Suppl","key":"2024013021124803800_bib25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cncr.11129","article-title":"Role of endothelin-1 in osteoblastic bone metastases","volume":"97","author":"Guise","year":"2003","journal-title":"Cancer"},{"key":"2024013021124803800_bib26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1096-9896(199907)188:3<278::AID-PATH358>3.0.CO;2-G","article-title":"Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: Implications for paracrine growth","volume":"188","author":"Doherty","year":"1999","journal-title":"J Pathol"},{"issue":"8 Suppl","key":"2024013021124803800_bib27","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1581::AID-CNCR8>3.0.CO;2-N","article-title":"Mechanisms of the development of osteoblastic metastases","volume":"80","author":"Goltzman","year":"1997","journal-title":"Cancer"},{"key":"2024013021124803800_bib28","first-page":"7883","article-title":"Solbule receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"2024013021124803800_bib29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1359\/jbmr.2002.17.2.192","article-title":"In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis","volume":"17","author":"Childs","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"3 Suppl","key":"2024013021124803800_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.11133","article-title":"Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: Novel therapeutic targets in myeloma","volume":"97","author":"Oyajobi","year":"2003","journal-title":"Cancer"},{"key":"2024013021124803800_bib31","first-page":"1713","article-title":"Evaluation of metastatic potential in prostate carcinoma: An in vivo model","volume":"25","author":"Angelucci","year":"2004","journal-title":"Int J Oncol"},{"key":"2024013021124803800_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/mthe.2001.0423","article-title":"Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4","volume":"4","author":"Peng","year":"2001","journal-title":"Mol Ther"},{"key":"2024013021124803800_bib33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1172\/JCI15153","article-title":"Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4","volume":"110","author":"Peng","year":"2002","journal-title":"J Clin Invest"},{"key":"2024013021124803800_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2106\/00004623-200401000-00013","article-title":"Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model","volume":"86","author":"Hannallah","year":"2004","journal-title":"J Bone Joint Surg Am"},{"key":"2024013021124803800_bib35","first-page":"107","article-title":"The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone","volume":"25","author":"Gamradt","year":"2004","journal-title":"Anticancer Res"},{"key":"2024013021124803800_bib36","first-page":"3194","article-title":"Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo","volume":"57","author":"Uy","year":"1997","journal-title":"Cancer Res"},{"key":"2024013021124803800_bib37","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-04-2033","article-title":"Osteoprotegerin in prostate cancer bone metastasis","volume":"65","author":"Corey","year":"2005","journal-title":"Cancer Res"},{"key":"2024013021124803800_bib38","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1359\/jbmr.2003.18.10.1882","article-title":"Characterization of C4\u20132 prostate cancer bone metastases and their response to castration","volume":"18","author":"Pfetzenmaier","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013021124803800_bib39","first-page":"3625","article-title":"Splenic, thymic, bony and lymph node metastases from orthotopic human lung carcinomas in immunocompromised mice","volume":"20","author":"Hastings","year":"2000","journal-title":"Anticancer Res"},{"key":"2024013021124803800_bib40","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1158\/0008-5472.CAN-05-2630","article-title":"Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway","volume":"65","author":"Bendre","year":"2005","journal-title":"Cancer Res"},{"key":"2024013021124803800_bib41","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/cyto.1999.0508","article-title":"Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: Importance of BMP2","volume":"11","author":"Arnold","year":"1999","journal-title":"Cytokine"},{"key":"2024013021124803800_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bbrc.2004.02.016","article-title":"BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells","volume":"316","author":"Wen","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"2024013021124803800_bib43","first-page":"277","article-title":"Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells","volume":"63","author":"Pouliot","year":"2003","journal-title":"Cancer Res"},{"key":"2024013021124803800_bib44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature01245","article-title":"Structural basis of BMP signalling inhibition by the cystine knot protein Noggin","volume":"420","author":"Groppe","year":"2002","journal-title":"Nature"},{"issue":"Suppl 3","key":"2024013021124803800_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2106\/00004623-200300003-00010","article-title":"Structural basis of BMP signaling inhibition by Noggin, a novel twelve-membered cystine knot protein","volume":"85","author":"Groppe","year":"2003","journal-title":"J Bone Joint Surg Am"},{"key":"2024013021124803800_bib46","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0016-5085(99)70024-7","article-title":"Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo","volume":"116","author":"Kleeff","year":"1999","journal-title":"Gastroenterology"},{"key":"2024013021124803800_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/bbrc.1999.0715","article-title":"Bone morphogenetic protein-2 enchances ostetoclast formation mediated by interleukin-1 alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2","volume":"259","author":"Koide","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl","key":"2024013021124803800_bib48","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1097\/01.blo.0000093847.72468.2f","article-title":"Molecular mechanisms of bone metastasis and therapeutic implications","volume":"415","author":"O'Keefe","year":"2003","journal-title":"Clin Orthop"},{"key":"2024013021124803800_bib49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Ann Oncol"},{"key":"2024013021124803800_bib50","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: A randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"2024013021124803800_bib51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3816\/CGC.2002.n.016","article-title":"Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone","volume":"1","author":"Saad","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"2024013021124803800_bib52","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.pcan.4500752","article-title":"Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients","volume":"7","author":"Rodrigues","year":"2004","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.060706","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/10\/1571\/56483169\/5650211009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/21\/10\/1571\/56483169\/5650211009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:47:18Z","timestamp":1710341238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/21\/10\/1571-1580\/7593200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,1]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2006,10,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.060706","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,10,1]]},"published":{"date-parts":[[2006,10,1]]}}}